391 related articles for article (PubMed ID: 23239905)
1. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.
Garcovich M; Zocco MA; Roccarina D; Ponziani FR; Gasbarrini A
World J Gastroenterol; 2012 Dec; 18(46):6693-700. PubMed ID: 23239905
[TBL] [Abstract][Full Text] [Related]
2. Management of hepatic encephalopathy: role of rifaximin.
Zeneroli ML; Avallone R; Corsi L; Venturini I; Baraldi C; Baraldi M
Chemotherapy; 2005; 51 Suppl 1():90-5. PubMed ID: 15855752
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota and hepatic encephalopathy.
Dhiman RK
Metab Brain Dis; 2013 Jun; 28(2):321-6. PubMed ID: 23463489
[TBL] [Abstract][Full Text] [Related]
4. Current concepts in the pathophysiology and management of hepatic encephalopathy.
Frederick RT
Gastroenterol Hepatol (N Y); 2011 Apr; 7(4):222-33. PubMed ID: 21857820
[TBL] [Abstract][Full Text] [Related]
5. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy for hepatic encephalopathy.
Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of hepatic encephalopathy in cirrhosis.
Romero-Gómez M
Expert Opin Pharmacother; 2010 Jun; 11(8):1317-27. PubMed ID: 20384539
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
9. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Prakash RK; Kanna S; Mullen KD
Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.
Ahluwalia V; Wade JB; Heuman DM; Hammeke TA; Sanyal AJ; Sterling RK; Stravitz RT; Luketic V; Siddiqui MS; Puri P; Fuchs M; Lennon MJ; Kraft KA; Gilles H; White MB; Noble NA; Bajaj JS
Metab Brain Dis; 2014 Dec; 29(4):1017-25. PubMed ID: 24590688
[TBL] [Abstract][Full Text] [Related]
11. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
12. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis.
Zhu R; Liu L; Zhang G; Dong J; Ren Z; Li Z
Biosci Rep; 2023 Jun; 43(6):. PubMed ID: 37279097
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota-related complications in cirrhosis.
Gómez-Hurtado I; Such J; Sanz Y; Francés R
World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
[TBL] [Abstract][Full Text] [Related]
15. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
16. [Role of rifaximin in the treatment of hepatic encephalopathy].
Sanchez-Delgado J; Miquel M
Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome.
Yu X; Jin Y; Zhou W; Xiao T; Wu Z; Su J; Gao H; Shen P; Zheng B; Luo Q; Li L; Xiao Y
Front Cell Infect Microbiol; 2021; 11():761192. PubMed ID: 35118004
[TBL] [Abstract][Full Text] [Related]
19. Linkage of gut microbiome with cognition in hepatic encephalopathy.
Bajaj JS; Ridlon JM; Hylemon PB; Thacker LR; Heuman DM; Smith S; Sikaroodi M; Gillevet PM
Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G168-75. PubMed ID: 21940902
[TBL] [Abstract][Full Text] [Related]
20. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.
Bajaj JS; Barbara G; DuPont HL; Mearin F; Gasbarrini A; Tack J
Dig Liver Dis; 2018 Aug; 50(8):741-749. PubMed ID: 29807873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
